ContraFect Corporation (NASDAQ: CFRXU)

contrafect-176

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the … Continue reading


Medgenics, Inc. (MDGN)

mdgn-176

Medgenics is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company has developed proprietary technology called the Biopump Platform, which uses the patient’s own tissue to continuously produce and deliver the patient’s own protein therapy. … Continue reading


Medicinova (MNOV)

mnov-176

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 … Continue reading


Fibrocell Science (FCSC)

fcsc-176

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, … Continue reading


TONIX Pharmaceuticals (TNXP)

tnxp-176

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves … Continue reading


TG Therapeutics (TGTX)

tgtx-176

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently we are developing ublituximab (TGTX-1101), a novel, third … Continue reading


InspireMD, Inc. (NSPR)

inspiremd-176

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission … Continue reading


DARA BioSciences (DARA)

dara-176

DARA is a pharmaceutical development company that acquires promising therapeutic molecules in early stage development. It then expedites development through proof-of-concept in humans for subsequent partnering, sale or out-licensing to large healthcare and pharmaceutical companies. The effective implementation of this … Continue reading


Cipher Pharmaceuticals (DND.TO)

dnd-to-176

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of currently marketed molecules that have been improved through advanced drug delivery technologies. Cipher’s lead compound, CIP-FENOFIBRATE, is marketed in the United States by Kowa Pharmaceuticals America under … Continue reading


Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company’s two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis and multiple … Continue reading


SANUWAVE Health, Inc.

snwv-176

SANUWAVE Health, Inc. is an emerging regenerative medicine company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures.  SANUWAVE’s portfolio of products and product candidates activate … Continue reading


22nd Century Group, Inc. (XXII)

XXII-176

Founded in 1998, 22nd Century Limited, LLC (22nd Century) is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and … Continue reading


Galapagos N.V. (GLPGA)

glpga-176

Galapagos is a drug discovery company with two operating divisions: drug discovery and BioFocus DPI, Galapagos’ service division. Galapagos’ drug discovery division aims to develop novel, disease-modifying drugs in selected bone and joint disease areas for which there is a … Continue reading


Crucell N.V. (CRXL)

crxl-176

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private … Continue reading


Ventrus Biosciences (VTUS)

vtus-176

Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence. There are approximately 12.5 million Americans suffering from hemorrhoids, 7 million from fecal incontinence … Continue reading


VIA Pharmaceuticals, Inc. (VIA)

via-176

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA’s lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in plaque, which is an underlying cause … Continue reading


Threshold Pharmaceuticals, Inc. (THLD)

thld-176

Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline … Continue reading


Mediware Information Systems, Inc. (MEDW)

medw-176

Mediware delivers interoperable best-of-breed software systems that integrate with electronic medical records to improve efficiencies and address safety concerns enabling healthcare organizations to improve care processes while decreasing costs. Core Mediware solutions include blood management technologies for hospitals and blood … Continue reading


Lpath, Inc. (LPTN)

lptn-176

Lpath, Inc., headquartered in San Diego, California, is the category leader in bioactive-lipid-targeted therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP(TM) is an antibody against S1P that is presently … Continue reading


Cardiogenics Holdings, Inc. (CGNH)

cgnh-176

Through its operating subsidiaries, the Company develops its Point-Of-Care analyzer and products targeting the immunoassay segment of the IVD market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic … Continue reading